

The 9th International Advanced Course on Vaccinology in Asia Pacific Regions

IVI, Seoul, May 11-16, 2009

DRAFT AGENDA

DAY 1: Monday, May 11, 2009

900 930 Welcome address and IVI introduction J Clemens

EPIDEMIOLOGY

Chairperson: Ian Gust

930 1030 Observational methods in vaccine evaluation A Lopez TAB 1

1030 1045 Coffee break

1045 1215 Periods and measures of transmissibility J Kuritsky, A
Amarasinghe, O
Wichmann TAB 2

1215 1330 Lunch

1330 1400 Immunization for disease control, elimination, and eradication J Partridge TAB 3

1400 1430 Surveillance: definition, goals, and methodology M Favorov TAB 4

1430 1500 Ethical principles and review P Kilgore TAB 5

1500 1515 Coffee break

IMMUNOBIOLOGY

Chairperson: Mina Kweon

1515 1600 Vaccine concepts: immunological basis C Czerkinsky TAB 6

1600 1645 Basic principle of immune responses: innate versus adaptive immunity H Kiyono TAB 7

1730 2000 **Welcome reception** **at the IVI Lobby**

DAY 2: Tuesday, May 12, 2009

MOVING FROM DISCOVERY TO LICENSED PRODUCT

Chairperson: Paul Kilgore

830 900 Antigen delivery systems (adjuvants, DNA-based vaccines, recombinant viral vaccines) M Liu TAB 8

900 930 Vaccine delivery systems (nasal, oral, aerosol, dermal, jet injector delivery) M Liu TAB 9

930 1000 Immunological basis of mucosal vaccines M Kweon TAB 10

1000 1015 Coffee break

1015 1100 Development and GMP production of vaccines R Carbis TAB 11

1100 1130 Managing intellectual property in vaccine development R Mahoney TAB 12

1130 1230 Lunch

Chairperson: Rodney Carbis

1230 1310 Development of clinical read-outs for the evaluation of a conjugate pneumococcal vaccine P Lestrade TAB 13

1310 1350 Phase I-III pneumococcal conjugate clinical trials: case study P Kilgore TAB 14

1350 1400 Coffee break

1400 1500 **IVI laboratory tour** R Carbis

1530 **Seoul sightseeing**

DAY 3: Wednesday, May 13, 2009

MOVING FROM LICENSING TO INTRODUCTION

Chairperson: Francis Andre

900	1030	New vaccine evaluation: phase I - III	J Clemens	TAB 15
1030	1045	Coffee break		
1045	1125	Phase 3B studies: demonstration projects	J Clemens	TAB 16
1125	1205	Post-marketing surveillance (Phase 4 studies)	M Beatty	TAB 17
1205	1300	Lunch		

MOVING FROM LICENSING TO INTRODUCTION (2)

Chairperson: Joel Kuritsky

1300	1330	Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a re-analysis	J Clemens	TAB 18
1330	1430	The changing regulatory environment: the rotavirus vaccine case	I Gust	TAB 19
1430	1445	Coffee break		
1445	1515	Asian regulatory perspective and trends	E Michael	TAB 20
1515	1600	AEFIs and risk communication	F Andre	TAB 21
1600	1615	Coffee break		
1615	1745	Round table discussion: The science, practice, public opinion - a pragmatic approach?	Chaired by F Andre Participants: I Gust, E Michael, J Kuritsky	

DAY 4: Thursday, May 14, 2009

PRODUCT DEVELOPMENT PARTNERSHIPS

900	1030	The Pediatric Dengue Vaccine Initiative and Dengue Vaccines: a case study overview lectures - epidemiology, vaccines, diagnostics and vaccine access	H Margolis, R Mahoney, M Beatty, O Wichmann	TAB 22
1030	1200	Break-out Groups: identification of barriers to evaluation and introduction of dengue vaccines and how to overcome	H Margolis, J Kuritsky, R Mahoney, M Beatty, O Wichmann	TAB 23
		Coffee break (during the breakout session)		
1200	1230	Group discussion: conclusions from breakout groups and discussion	J Kuritsky	
1230	1330	Lunch		

PRODUCT DEVELOPMENT PARTNERSHIPS (2)

Chairperson: Daniele Kohl

1330	1530	PPPs: 3 models of accelerating the development and introduction of developing country vaccines with local producers/big pharma: Cholera Vaccines (40 mins) Malaria vaccines (40 mins) HPV vaccines (40 mins)	A Lopez K Amfo C Llave	TAB 24 TAB 25 TAB 26
1530	1545	Coffee break		
1545	1615	Negotiating partnerships with the private sector	R Mahoney	TAB 27
1615	1715	Technology transfer Technology transfer: an IVI perspective Development and technology transfer of cost-effective conjugate vaccine against <i>Haemophilus influenzae</i> type b	G Smith M Beurret	TAB 28 TAB 29

DAY 5: Friday, May 15, 2009

MOVING FROM LICENSURE TO USE

Chairperson: Richard Mahoney

900	1000	Special Lecture (1): The changing face of the vaccine industry	I Gust	TAB 30
1000	1045	Health economics: principles and methods	J Kuritsky	TAB 31
1045	1100	Coffee break		
1100	1145	Introduction of vaccines and its economic impact	K Saleh	TAB 32
1145	1230	Lunch		
Introduction of new vaccines with emphasis in the Asia-Pacific regions:				
1230	1300	Hib vaccine introduction in the region	K Edmond	TAB 33
1300	1330	Rotavirus vaccine introduction	T Nelson	TAB 34
1330	1400	Discussion on participant's practical experiences		
1400	1415	Coffee break		

Programmatic Considerations:

1415	1445	Financing mechanisms for vaccines: an overview	R Mahoney	TAB 35
1445	1515	Financing mechanisms for GAVI eligible countries	K Saleh	TAB 36
1515	1545	Round table discussion	Chaired by F Andre J Kuritsky, K Saleh, R Mahoney	
1545	1600	Coffee break		

Chairperson: Tony Nelson

1600	1640	Sharing experience: injection safety assessment and adverse event monitoring Discussion on participants' practical experiences	A Amarasinghe	TAB 37
Sharing experience: vaccine introduction in GAVI Programs - cold chain, logistics				
1640	1710	WHO perspective	S Kone	TAB 38
1710	1740	Industry perspective	D Kohl	TAB 39
1740	1820	Discussion on participants' practical experiences		

DAY 6: Saturday, May 16, 2009

Chairperson: J Clemens

900	1000	Special Lecture (2): Vaccines: The story so far	F Andre	TAB 40
1000	1030	Coffee break		
1030	1130	Closing ceremony	J Clemens	
1130	1400	Lunch		